Welcome to our dedicated page for Lisata Therapeutics news (Ticker: LSTA), a resource for investors and traders seeking the latest updates and insights on Lisata Therapeutics stock.
Overview
Lisata Therapeutics Inc (LSTA) is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies designed to treat advanced solid tumors and other significant diseases. Leveraging cutting-edge peptide technology, the company is focused on addressing major unmet medical needs in oncology by enhancing the delivery of anti-cancer drugs through a novel uptake pathway. Keywords such as clinical-stage pharmaceutical, solid tumors, and oncology are essential in understanding the company's core focus.
Innovative Technologies and Product Pipeline
At the heart of Lisata Therapeutics' robust research and development efforts is its investigational product, certepetide. This cyclic iRGD peptide is engineered to activate a unique uptake pathway, enabling co-administered or tethered anti-cancer drugs to selectively penetrate and accumulate within solid tumors. By effectively modifying the tumor microenvironment and reducing its immunosuppressive characteristics, certepetide offers an advanced method to enhance the efficacy of conventional chemotherapy, immunotherapies, and RNA-based therapeutics.
The company employs its proprietary CendR Platform technology as a foundation for its research, supporting multiple clinical trials across various tumor types. With studies evaluating the safety, tolerability, and therapeutic potential of certepetide in combination with standard-of-care regimens, Lisata is actively exploring opportunities in both first-line and second-line therapeutic settings. This strategic approach facilitates a comprehensive evaluation of the product across a range of cancers, including pancreatic, cholangiocarcinoma, glioblastoma, colon, and melanoma.
Research & Development and Strategic Collaborations
Lisata Therapeutics stands out for its commitment to extensive research and collaboration. The company has established noteworthy partnerships with academic institutions, biotechnology firms, and diagnostic innovators to accelerate the clinical development of its product candidates. These collaborations not only reflect the company’s expertise in translational medicine but also support the integration of novel diagnostic strategies, such as advanced imaging and molecular assays, to monitor therapeutic response accurately.
Through its diversified clinical trial portfolio, Lisata is engaged in both early and pivotal phase studies, evaluating the role of certepetide in enhancing drug delivery and achieving better patient outcomes. The company’s strategic initiatives have been structured to address the challenges inherent in targeting advanced solid tumors and to provide detailed insights into the mechanism of drug-tumor interactions.
Market Position and Significance
Within the competitive landscape of oncology therapeutics, Lisata Therapeutics is recognized for its innovative approach to drug delivery and tumor targeting. The company's scientific strategy, rooted in the modification of the tumor microenvironment and enhanced drug penetration, offers substantial differentiation from other therapeutic modalities. This focus on leveraging peptide technology to improve the performance of co-administered anti-cancer agents positions Lisata as an important contributor to the evolving cancer treatment paradigm.
Lisata’s comprehensive approach—spanning drug development, strategic partnerships, and collaborative research—underscores its commitment to advancing treatment options for patients with difficult-to-treat malignancies. The scientific rigor applied in its clinical studies and the transparent dissemination of clinical milestones underscore the company’s dedication to improving our understanding of tumor biology and therapeutic innovation.
Clinical Trials and Future Directions
While Lisata is known for its robust pipeline and forward-thinking clinical programs, the company remains focused on providing critical data from its ongoing investigations. The breadth of its trial portfolio not only includes evaluations in solid tumor oncology but also extends into exploring non-oncology applications, reflecting the versatility of its technology platform. Each study is designed to yield actionable insights regarding therapeutic activity and safety, thereby reinforcing the scientific competence and credibility of the company.
In summary, Lisata Therapeutics exemplifies a modern biopharmaceutical company that combines advanced peptide technology with a strategic, research-driven approach to address some of the most challenging therapeutic needs in oncology today. Its comprehensive and methodical R&D efforts, bolstered by strategic collaborations and a clear focus on enhancing drug delivery, make it a significant entity within the field of targeted cancer therapies.
Lisata Therapeutics (NASDAQ: LSTA) has been named 'Specialized BioTherapeutics Company of the Year' at the 2024 BioTech Breakthrough Awards. The company is recognized for its innovative CendR Platform® technology, which enhances tumor-targeted drug delivery. Their lead candidate, certepetide, has shown promising results in pancreatic cancer treatment and holds multiple FDA designations including Fast Track and Orphan Drug status for various cancers.
The company's therapeutic approach focuses on modifying the tumor microenvironment to improve the effectiveness of existing anti-cancer treatments. Certepetide is currently being evaluated in clinical trials for multiple advanced solid tumors, including pancreatic, cholangiocarcinoma, glioblastoma, colon cancer, appendiceal cancer, and melanoma, with potential applications in non-oncologic conditions like endometriosis.
Lisata Therapeutics (LSTA) reported Q3 2024 financial results and provided updates on its development portfolio centered around certepetide, a drug candidate for treating advanced solid tumors. The company reported operating expenses of $5.3 million, down 10.5% year-over-year, and net losses of $4.9 million. Cash position stands at $35.9 million, expected to fund operations into early 2026.
Multiple clinical trials are ongoing, including the Phase 2b ASCEND trial for pancreatic cancer, with preliminary results expected in January 2025. The BOLSTER trial for cholangiocarcinoma achieved complete enrollment ahead of schedule, with topline data expected mid-2025.
Lisata Therapeutics (NASDAQ: LSTA) and Valo Therapeutics have announced a preclinical research collaboration to study the combination of Lisata's certepetide with ValoTx's PeptiCRAd platform and a checkpoint inhibitor in a melanoma mouse model. The study aims to build on previous research showing certepetide's synergistic effects with immunotherapies. ValoTx will conduct the research while Lisata provides the certepetide product. The collaboration targets melanoma treatment, which currently has a 35-60% response rate to checkpoint inhibitor therapies and causes approximately 58,000 deaths annually worldwide.
Lisata Therapeutics (Nasdaq: LSTA), a clinical-stage pharmaceutical company focused on developing therapies for advanced solid tumors and other serious diseases, announced it will release its third quarter 2024 financial results on Tuesday, November 12, 2024, after market close. The company will host a conference call at 4:30 p.m. Eastern time. Participants must pre-register for the call, and a live webcast will be available on Lisata's website, remaining accessible for 12 months after the event.
Lisata Therapeutics (Nasdaq: LSTA), a clinical-stage pharmaceutical company focused on advanced solid tumor treatments, has announced its participation in three major industry events this November. The company will be present at BIO-Europe in Stockholm (Nov 4-6, with virtual sessions Nov 12-13), where VP Tariq Imam will conduct one-on-one meetings. At the PEGS Europe Summit in Barcelona (Nov 5-7), CEO David J. Mazzo will present on Nov 5 at 3:20 p.m. CEST. Additionally, Dr. Mazzo will present at the LSX Inv€$tival showcase in London's Tobacco Dock on Nov 18 at 1:00 p.m. GMT.
Lisata Therapeutics (Nasdaq: LSTA) has entered into a sponsored research agreement with the University of Cincinnati to study certepetide combined with bevacizumab for treating endometriosis. The research aims to leverage certepetide's selective targeting of endometrial tissue through surface integrin and neuropilin-1 receptors. While bevacizumab has shown efficacy in endometriosis treatment, its high dosage requirements cause systemic side effects. The partnership targets endometriosis, a condition affecting 6.5 million U.S. women, characterized by uterine tissue growth outside the uterus, causing pain and fertility issues.
Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company, has announced its participation in three upcoming industry and investor events in October 2024. These events include:
1. Pharma Partnering U.S. Summit (October 16-17) in Boston, MA, where Tariq Imam, VP of Business Development and Operations, will conduct one-on-one meetings.
2. BioFuture (October 28-30) in New York, NY, featuring a presentation by David J. Mazzo, PhD, President and CEO, on October 28 at 11:00 a.m. ET.
3. 17th Annual LD Micro Main Event (October 28-30) in Los Angeles, CA, where David J. Mazzo will present on October 29 at 11:00 a.m. PT.
These events offer opportunities for investors and industry professionals to learn more about Lisata's innovative therapies for advanced solid tumors and other serious diseases.
Lisata Therapeutics (Nasdaq: LSTA) has announced the treatment of the first patient in the second-line cholangiocarcinoma (CCA) cohort of the BOLSTER trial. This expansion follows the successful completion of enrollment in the first-line CCA cohort. The decision to initiate this cohort was based on recommendations from investigators in the first-line study. The BOLSTER trial is a Phase 2a, double-blind, placebo-controlled, randomized, multi-center study evaluating certepetide in combination with standard-of-care for first- or second-line CCA patients. This expansion aims to improve outcomes for patients who have progressed after first-line standard-of-care therapy alone.
Lisata Therapeutics (NASDAQ: LSTA), a clinical-stage pharmaceutical company, has announced its participation in two major industry events in September 2024. The company will be part of the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, with an on-demand virtual presentation available from September 9. Additionally, Lisata will present at the 2024 LSX World Congress USA on September 12 at 11:15 a.m. ET in Boston.
Dr. David J. Mazzo, President and CEO of Lisata, will be the presenter at both events. These conferences provide Lisata with opportunities to showcase its innovative therapies for advanced solid tumors and other serious diseases to investors and industry professionals.
Lisata Therapeutics (Nasdaq: LSTA) has received FDA Orphan Drug Designation for certepetide in treating cholangiocarcinoma, a rare and aggressive cancer. This designation is a significant step towards addressing the unmet need for new therapies in this area. Lisata is currently conducting the BOLSTER trial, a Phase 2a study evaluating certepetide for first- and second-line cholangiocarcinoma treatment. The trial is a double-blind, placebo-controlled, multi-center, randomized study taking place in the U.S. This development underscores Lisata's commitment to developing innovative therapies for advanced solid tumors and other serious diseases.
FAQ
What is the current stock price of Lisata Therapeutics (LSTA)?
What is the market cap of Lisata Therapeutics (LSTA)?
What is the primary focus of Lisata Therapeutics?
How does Lisata's investigational product, certepetide, work?
What technology platform supports Lisata's research and development?
In which types of cancer is Lisata focusing its clinical trials?
What is the significance of Lisata's strategic collaborations?
How do Lisata's solutions differentiate it from other oncology therapeutics?
Are there any non-oncology applications being explored by Lisata?
What role do clinical trials play in Lisata's development strategy?
